Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5887_Библиотеки_им_академика_М_И_Перельмана
.pdf
236
https://t.me/medicina_free
Calabrese V et al., “Novel Targets for Therapeutic Intervention in Neurodegenerative
Disorders,” British Journal of Clinical Pharmacology 66, no. 5 (2010a): 594–617.
Calabrese V et al., “Oxidative Stress, Redox Homeostasis and Cellular Stress Response in
Ménière’s Disease: Role of Vitagenes,” Neurochemical Research 35, no. 12 (December3,
2010b): 2208–17, https://doi.org/10.1007/s11064-010-0304-2.
Calabrese V et al., “Biochimica et Biophysica Acta Cellular Stress Responses, Hormetic
Phytochemicals and Vitagenes in Aging and Longevity,” BBA - Molecular Basis of
Disease 1822, no. 5 (2012): 753–783, https://doi.org/10.1016/j.bbadis.2011.11.002.
Calabresec V et al., “Hormesis, Cellular Stress Response, and Redox Homeostasis in Autism
Spectrum Disorders,” Journal of Neuroscience Research 94, no. 12 (2016): 1–11, https://
doi.org/10.1002/jnr.23893.
Calabrese EJ, EJ Stanek, and MA Nascarella, “Evidence for Hormesis in Mutagenicity Dose–
Response Relationships,” Mutation Research/Genetic Toxicology and Environmental
Mutagenesis 726, no. 2 (December 24, 2011): 91–97, https://doi.org/10.1016/J.MRGEN
TOX.2011.04.006.
Chen CM et al., “Novel Regimen Through Combination of Memantine and Tea Polyphenol
for Neuroprotection Against Brain Excitotoxicity,” Journal of Neuroscience Research
86, no. 12 (September 1, 2008): 2696–2704, https://doi.org/10.1002/JNR.21706.
Conte A, S Pellegrini, and D Tagliazucchi, “Synergistic Protection of PC12 Cells from
β-Amyloid Toxicity by Resveratrol and Catechin,” Brain Research Bulletin 62, no. 1
(2003): 29–38, https://doi.org/10.1016/j.brainresbull.2003.08.001.
Davies C, and S Bhattacharyya, “Cannabidiol as a Potential Treatment for Psychosis,”
Therapeutic Advances in Psychopharmacology 9 (2019): 204512531988191, https://doi.
org/10.1177/2045125319881916.
Donohoe DR, and SJ Bultman, “Metaboloepigenetics: Interrelationships between Energy
Metabolism and Epigenetic Control of Gene Expression,” Journal of Cellular Physiology
227, no. 9 (September 1, 2012): 3169–3177, https://doi.org/10.1002/JCP.24054.
Eggers C et al., “Novel Cannabis Flavonoid, Cannavin A Displays Both a Hormetic and
Neuroprotective Prole Against Amyloid β-Mediated Neurotoxicity in PC12 Cells:
Comparison With Geranylated Flavonoids, Mimulone and Diplacone,” Biochemical
Pharmacology 169, no. August (2019): 113609, https://doi.org/10.1016/j.bcp.2019.08.011.
Eghbali S et al., “Therapeutic Effects of Punica Granatum (Pomegranate): An Updated
Review of Clinical Trials,” Journal of Nutrition and Metabolism 2021 (2021), https://
doi.org/10.1155/2021/5297162.
Elmazoglu Z et al., “Luteolin Protects Microglia Against Rotenone-Induced Toxicity in a
Hormetic Manner Through Targeting Oxidative Stress Response, Genes Associated
With Parkinson’s Disease and Inammatory Pathways,” Drug and Chemical Toxicology
43, no. 1 (2020): 96–103, https://doi.org/10.1080/01480545.2018.1504961
Falchetti R et al., “Effects of Resveratrol on Human Immune Cell Function,” Life Sciences
70, no. 1 (2001): 81–96, https://doi.org/10.1016/S0024-3205(01)01367-4.
Flier VD et al., “Cognitive Decline in AD and Mild Cognitive Impairment Is Associated with
Global Brain Damage.” Neurology 59, no. 6 (2002): 874–879, https://doi.org/10.1212/
WNL.59.6.874.
Forni C et al., “Benecial Role of Phytochemicals on Oxidative Stress and Age-Related
Diseases,” BioMed Research International 2019, no. Figure 1 (2019), https://doi.org/
10.1155/2019/8748253.
Gao X et al., “Immunomodulatory Activity of Curcumin: Suppression of Lymphocyte
Proliferation, Development of Cell-Mediated Cytotoxicity, and Cytokine Production
in Vitro,” Biochemical Pharmacology 68, no. 1 (2004): 51–61, https://doi.org/10.1016/j.
bcp.2004.03.015.
Gao Y et al., “Protopanaxtriol Protects Against 3-Nitropropionic Acid-Induced Oxidative
Stress in a Rat Model of Huntington’s Disease,” Acta Pharmacologica Sinica 36, no. 3
(2015): 311–322, https://doi.org/10.1038/aps.2014.107.
NeuroPhytomedicine
237Future Trends and Directives for Research
https://t.me/medicina_free
Gocmez SS, TD Şahin, Y Yazir, G Duruksu, FC Eraldemir, S Polat, and T Utkan. “Resveratrol
Prevents Cognitive Decits by Attenuating Oxidative Damage and Inammation in
Rat Model of Streptozotocin Diabetes Induced Vascular Dementia,” Physiology &
Behavior 201, (2019): 198–207.
Hammad MA et al., “Prescribing Statins Among Patients With Type 2 Diabetes: The Clinical
Gap between the Guidelines and Practice,” Journal of Research in Medical Sciences
24, no. 1 (2019): 1–9, https://doi.org/10.4103%2Fjrms.JRMS_100_18.
Han YH et al., “Neuroprotective Effects of Resveratrol Against β-Amyloid-Induced
Neurotoxicity in Rat Hippocampal Neurons: Involvement of Protein Kinase C,” British
Journal of Pharmacology 141, no. 6 (2004): 997–1005, https://doi.org/10.1038/sj.bjp.
0705688.
Haslam, E, “Practical Polyphenolics: From Structure to Molecular Recognition and Physiological
Action,” Trends in Food Science & Technology 10, (1998): 339.
Jagetia GC, and BB Aggarwal, “‘Spicing up’ of the Immune System by Curcumin,” Journal of
Clinica l Immunology 27, no. 1 (20 07): 19 –35, https://doi.org/10.1007/s10875-00 6-9066-7.
Jang M et al., “Korean Red Ginseng Extract Attenuates 3-Nitropropionic Acid-Induced
Huntington’s-Like Symptoms,” Evidence-Based Complementary and Alternative Medicine
2013 (2013): 8–10, https://doi.org/10.1155/2013/237207.
Jin F et al., “Neuroprotective Effect of Resveratrol on 6-OHDA-Induced Parkinson’s Disease
in Rats,” European Journal of Pharmacology 600, no. 1–3 (2008): 78–82, https://doi.
org/10.1016/j.ejphar.2008.10.005.
Joseph JA, NA Denisova, G Arendash, M Gordon, D Diamond, B Shukitt-Hale, and D
Morgan. “Blueberry Supplementation Enhances Signaling and Prevents Behavioral
Decits in an Alzheimer Disease Model,” Nutritional Neuroscience 6, no. 3 (2003):
153–162, https://doi.org/10.1080/1028415031000111282. PMID: 12793519.
Kanthasamy AG, M Ay, J Luo, M Langley, H Jin, V Ananthara m, and A Kanthasa my, Mole cular
Mechanisms Underlying Protective Effects of Quercetin Against Mitochondrial
Dysfunction and Progressive Dopaminergic Neurodegeneration in Cell Culture and
MitoPark Transgenic Mouse Models of Parkinson’s Disease. Journal of Neurochemistry
141, no. 5 (2017): 766–782, https://doi.org/10.1111/jnc.14033. Epub 2017 May 9. PMID:
28376279; PMCID: PMC5643047.
Kim HJ et al., “Oral Administration of Gintonin Attenuates Cholinergic Impairments by
Scopolami ne, Amyloid-β Protein , and Mouse Model of Alzheimer’s Disease,” Molecules
and Cells 38, no. 9 (2015): 796–805, https://doi.org/10.14348/molcells.2015.0116.
Kim J, “Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane
in Alzheimer’s Disease,” International Journal of Molecular Sciences 22, no. 6 (2021):
1–16, https://doi.org/10.3390/ijms22062929.
Kops GJ, RH Medema, J Glassford, MA Essers, PF Dijkers, PJ Coffer, EW Lam, and BM
Burgering, “Control of Cell Cycle Exit and Entry by Protein Kinase B-Regulated
Forkhead Transcription Factors,” Molecular and Cellular Biology 22, no. 7 (April 2002):
2025–2036, https://doi.org/10.1128/MCB.22.7.2025-2036.2002. PMID: 11884591; PMCID:
PMC133681.
Kumar GP, KR Anilakumar, and S Naveen, “Phytochemicals Having Neuroprotective
Properties from Dietary Sources and Medicinal Herbs,” Pharmacognosy Journal 7,
no. 1 (2015): 1–17.
Lee YJ et al., “Synergistic Anti-Cancer Effects of Resveratrol and Chemotherapeutic Agent
Clofarabine Against Human Malignant Mesothelioma MSTO-211H Cells,” Food
and Chemical Toxicology 52 (February 1, 2013): 61–68, https://doi.org/10.1016/J.
FCT.2012.10.060.
Lee YJ et al., “Knockdown of Bcl-XL Enhances Growth-Inhibiting and Apoptosis-Inducing
Effects of Resveratrol and Clofarabine in Malignant Mesothelioma H-2452 Cells,”
Journal of Korean Medical Science 29, no. 11 (November 4, 2014): 1464–1472, https://
doi.org/10.3346/JKMS.2014.29.11.1464.
238
https://t.me/medicina_free
Levites Y et al., “Involvement of Protein Kinase C Activation and Cell Survival/Cell Cycle
Genes in Green Tea Polyphenol (-)-Epigallocatechin 3-Gallate Neuroprotective
Action,” Journal of Biological Chemistry 277, no. 34 (2002): 30574–30580, https://doi.
org/10.1074/jbc.M202832200.
Lim GP et al., “The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid
Pathology in an Alzheimer Transgenic Mouse,” Journal of Neuroscience 21, no. 21
(2001): 8370–8377, https://doi.org/10.1523/jneurosci.21-21-08370.2001.
Lim W, KW Mudge, and F Vermeylen, “Effects of Population, Age, and Cultivation Methods
on Ginsenoside Content of Wild American Ginseng (Panax Quinquefolium),” Journal
of Agricultural and Food Chemistry 53, no. 22 (November 2, 2005): 8498–8505, https://
doi.org/10.1021/JF051070Y.
Liu H et al., “Allicin Protects PC12 Cells Against 6-OHDA-Induced Oxidative Stress and
Mitochondrial Dysfunction via Regulating Mitochondrial Dynamics” 710061, no. 277
(2015): 966–979, https://doi.org/10.1159/000430271.
Liu RH, “Potential Synergy of Phytochemicals in Cancer Prevention: Mechanism of Action,”
The Journal of Nutrition 134, no. 12 (December 1, 2004): 3479S–3485S, https://doi.
org/10.1093/JN/134.12.3479S.
Lum PT et al., “Protective Effect of Mangiferin on Memory Impairment: A Systematic
Review,” Saudi Journal of Biological Sciences 28, no. 1 (2021): 917–927, https://doi.
org/10.1016/j.sjbs.2020.11.037.
Maher P et al., “Erk Activation by the Polyphenols Fisetin and Resveratrol Provides
Neuroprotection in Multiple Models of Huntington’s Disease,” Human Molecular
Genetics 20, no. 2 (2011): 261–270, https://doi.org/10.1093/hmg/ddq460.
Mandal SM, A Roy, AK Ghosh, TK Hazra, A Basak, and OL Franco, “Challenges and Future
Prospects of Antibiotic Therapy: From Peptides to Phages Utilization,” Frontiers in
Pharmacology 5 May (May 13, 2014): 105, https://doi.org/10.3389/fphar.2014.00105.
PMID: 24860506; PMCID: PMC4027024.
Mandlekar S, J-L Hong, and A-N Tony Kong, “Modulation of Metabolic Enzymes by
Dietary Phytochemicals: A Review of Mechanisms Underlying Benecial Versus
Unfavorable Effects,” Current Drug Metabolism 7, no. 6 (2006): 661–675, https://doi.
org/10.2174/138920006778017795.
Mattson MP, and A Cheng, “Neurohormetic Phytochemicals: Low-Dose Toxins That Induce
Adaptive Neuronal Stress Responses,” Trends in Neurosciences 29, no. 11 (2006):
632–639, https://doi.org/10.1016/j.tins.2006.09.001.
Mert DG et al., “The Inuence of Quercetin on Recognition Memory and Brain
Oxidative Damage in a Ketamine Model of Schizophrenia,” Psychiatry and Clinical
Psychopharmacology 29, no. 1 (2019): 1–7, https://doi.org/10.1080/24750573.2018.144
2670.
Miller EK, and JD Cohen. “An Integrative Theory of Prefrontal Cortex Function.” Annual
Review of Neuroscience 24, (2001): 167–202, https://doi.org/10.1146/annurev.neuro.
24.1.167. PMID: 11283309.
Nadeem A et al., “Nrf2 Activator, Sulforaphane Ameliorates Autism-Like Symptoms
Through Suppression of Th17 Related Signalling and Recti Fi Cation of OxidantAntioxidant Imbalance in Periphery and Brain of BTBR T + Tf/J Mice,” Behavioural
Brain Research 364, no. November 2018 (2019): 213–224, https://doi.org/10.1016/j.
bbr.2019.02.031.
Naithani R et al., “Antiviral Activity of Phytochemicals: A Comprehensive Review,”
Mini-Reviews in Medicinal Chemistry 8, no. 11 (2008): 1106–1133, https://doi.org/
10.2174/138955708785909943.
Niculescu MD, and SH Zeisel, “Diet, Methyl Donors and DNA Methylation: Interactions
between Dietary Folate, Methionine and Choline,” The Journal of Nutrition 132, no. 8
(August 1, 2002): 2333S–2335S, https://doi.org/10.1093/JN/132.8.2333S.
NeuroPhytomedicine
Future Trends and Directives for Research
https://t.me/medicina_free
Okwu DE, “Phytochemical and Vitamin Content of Indigenous Spices of South Eastern
Nigeria,” Journal of Sustainable Agriculture and Environment 6 (2004): 30–34, https://
cir.nii.ac.jp/crid/1571135650688285824.
Parasramka MA et al., “MicroRNAs, Diet, and Cancer: New Mechanistic Insights on the
Epigenetic Actions of Phytochemicals,” Molecular Carcinogenesis 51, no. 3 (March 1,
2012): 213–230, https://doi.org/10.1002/MC.20822.
Poulose SM, MG Miller, and B Shukitt-Hale, “Role of Walnuts In Maintaining Brain Health
With Age,” Journal of Nutrition 144, no. 4 (2014): 561S–566S, https://doi.org/10.3945/
jn.113.184838.
Praag HV et al., “Plant-Derived Flavanol (-)Epicatechin Enhances Angiogenesis and
Retention of Spatial Memory in Mice,” Journal of Neuroscience 27, no. 22 (2007):
5869–5878, https://doi.org/10.1523/JNEUROSCI.0914-07.2007.
Quattrone A et al., “The Subacute Kvodopa Test for Evaluating Long-Duration Response
in Parclnson’s Disease,” Annals of Neurology 38, no. 3 (1995): 389–395. https://doi.
org/10.1002/ana.410380308. PMID: 7668824.
Sahebnasagh A et al., “Neurohormetic Phytochemicals in the Pathogenesis of Neurodegenerative
Diseases,” Immunity and Ageing 19, no. 1 (2022): 1–16, https://doi.org/10.1186/s12979-
022-00292-x.
Schwarcz G, B Karajgi, and R McCarthy, “Synthetic Δ-9-Tetrahydrocannabinol (Dronabinol)
Can Improve the Symptoms of Schizophrenia,” Journal of Clinical Psychopharmacology
29, no. 3 (2009): 255–258, https://doi.org/10.1097/JCP.0b013e3181a6bc3b.
Shibani F et al. “Effect of Oleuropein on Morphine-Induced Hippocampus Neurotoxicity and
Memory Impairments in Rats,” Naunyn Schmiedebergs Arch Pharmacol 392, no. 11
(2019): 1383–1391. https://doi.org/10.1007/s00210- 019-01678-3. PMID: 31236657.
Si H, and D Liu, “Genistein, a Soy Phytoestrogen, Upregulates the Expression of Human
Endothelial Nitric Oxide Synthase and Lowers Blood Pressure in Spontaneously
Hypertensive Rats,” The Journal of Nutrition 138, no. 2 (February 1, 2008): 297–304,
https://doi.org/10.1093/JN/138.2.297.
Singh K et al., “Sulforaphane Treatment of Autism Spectrum Disorder (ASD).” Biological
Sciences 111, no. 43 (2014): 15550–15555, https://doi.org/10.1073/pnas.1416940111.
Son TG, S Camandola, and MP Mattson, “Hormetic Dietary Phytochemicals,” NeuroMolecular
Medicine 10, no. 4 (December 10, 2008): 236–246, https://doi.org/10.1007/s12017-008-
8037-y. PMCID: PMC2635914.
Spencer JPE, “Beyond Antioxidants: The Cellular and Molecular Interactions of Flavonoids
and How These Underpin Their Actions on the Brain,” Proceedings of the Nutrition
Society 69, no. 2 (May 2010): 244–260, https://doi.org/10.1017/S0029665110000054.
Spencer JPE, D Vauzour, and C Rendeiro, “Flavonoids and Cognition: The Molecular
Mechanisms Underlying Their Behavioural Effects,” Archives of Biochemistry and
Biophysics 492, no. 1–2 (December 1, 2009): 1–9, https://doi.org/10.1016/J.ABB.2009.
10.003
Stefanska B et al., “Epigenetic Mechanisms in Anti-Cancer Actions of Bioactive
Food Components – The Implications in Cancer Prevention,” British Journal of
Pharmacology 167, no. 2 (September 1, 2012): 279–297, https://doi.org/10.1111/J.1476 -
5381.2012.02002.X.
Stefanska B et al., “Comparative Effects of Retinoic Acid, Vitamin D and Resveratrol Alone
and in Combination With Adenosine Analogues on Methylation and Expression
of Phosphatase and Tensin Homologue Tumour Suppressor Gene in Breast Cancer
Cells,” British Journal of Nutrition 107, no. 6 (March 28, 2012): 781–790, https://doi.
org/10.1017/S0007114511003631.
Tang ED et al., “Negative Regulation of the Forkhead Transcription Factor FKHR by Akt,”
Journal of Biological Chemistry 274, no. 24 (June 11, 1999): 16741–16746, https://doi.
org/10.1074/jbc.274.24.16741.
239
240 NeuroPhytomedicine
https://t.me/medicina_free
Tosetti F, DM Noonan, and A Albini, “Metabolic Regulation and Redox Activity as
Mechanisms for Angioprevention by Dietary Phytochemicals,” International Journal
of Cancer 125, no. 9 (2009): 1997–2003, https://doi.org/10.1002/ijc.24677.
Tsai CW et al., “Garlic Organosulfur Compounds Upregulate the Expression of the π Class of
Glutathione S-Transferase in Rat Primary Hepatocytes,” The Journal of Nutrition 135,
no. 11 (November 1, 2005): 2560–2565, https://doi.org/10.1093/JN/135.11.2560.
Urdaneta KE, MA Castillo, N Montiel, N Semprún-Hernández, N Antonucci, and D
Siniscalco. “Autism Spectrum Disorders: Potential Neuro-Psychopharmacotherapeutic
Plant-Based Drugs.” ASSAY and Drug Development Technologies 16, no. 8 (2018):
433–444.
Venkatalaksh mi P, V Vadivel, and P Brindha, “Role of Phytochemicals as Immunomodulatory
Agents: A Review,” International Journal of Green Pharmacy 10, no. 1 (2016): 1–18.
Vickers NJ, “Animal Communication: When I’m Calling You, Will You Answer Too?,”
Current Biology 27, no. 14 (July 24, 2017): R713–R715, https://doi.org/10.1016/J.
CUB.2017.05.064.
Wang J et al., “Connection between Systemic Inammation and Neuroinammation Underlies
Neuroprotective Mechanism of Several Phytochemicals in Neurodegenerative
Diseases,” Oxidative Medicine and Cellular Longevity 2018 (2018), https://doi.org/
10.1155/2018/1972714.
Wong JH, AM Barron, and JM Abdullah, “Mitoprotective Effects of Centella Asiatica (L.)
Urb.: Anti-Inammatory and Neuroprotective Opportunities in Neurodegenerative
Disease,” Frontiers in Pharmacology 12 (June 29, 2021): 687935, https://doi.org/10.3389/
fphar.2021.687935. PMID: 34267660; PMCID: PMC8275827.
Yadav DK, “Potential Therapeutic Strategies of Phytochemicals in Neurodegenerative
Disorders,” Current Topics in Medicinal Chemistry 21, no. 31 (December 2, 2021):
2814–2838, https://doi.org/10.2174/1568026621666211201150217.
Zappia M, Oliveri RL, Bosco D, Nicoletti G, Branca D, Caracciolo M, Napoli ID, Gambardella
A, Quattrone A. The long-duration response to L-dopa in the treatment of early PD.
Neurology. 2000 May 23;54(10):1910-5. doi: 10.1212/wnl.54.10.1910. PMID: 10822428.
Zhang C et al., “Berberine Protects Against 6-OHDA-Induced Neurotoxicity in PC12 Cells
and Zebrash Through Hormetic Mechanisms Involving PI3K/AKT/Bcl-2 and Nrf2/
HO-1 Pathways,” Redox Biology 11, no. September 2016 (2017): 1–11, https://doi.
org/10.1016/j.redox.2016.10.019.
Zhang Y et al., “Brief Communication by Sulfhydryl-Reactive Inducers of the KEAP1/
NRF2/ARE Pathway,” Chemistry & Biology 18, no. 11 (2011): 1355–1361, https://doi.
org/10.1016/j.chembiol.2011.09.008.
Zhao YN et a l., “Resveratrol Improves Lea rning and Memory i n Normally Aged Mice Th rough
MicroRNA-CREB Pathway,” Biochemical and Biophysical Research Communications
435, no. 4 (2013): 597–602, https://doi.org/10.1016/j.bbrc.2013.05.025.
Index
https://t.me/medicina_free
Note: Locators in italics represent gures and bold indicate tables in the text.
A
AC, see Afnity chromatography
Accelerated solvent extraction, 43
Acetoxy eugenol acetate, 191
3-O-Acetyl-11-keto-β-boswellic acid (AKBA),
Acetylcholinesterase (AChE), 8, 61, 191
Acetyl-CoA, 224
AChE, see Acetylcholinesterase
Acorus calamus, 99
ACTH, see Adrenocorticotropic hormone
AD, see Alzheimer’s disease
Adaptive responses, stimulation of, 223–224
Adenosine monophosphate (AMP), 224
ADHD, see Attention decit/hyperactivity
AD mouse models, see Atopic dermatitis mouse
Adrenocorticotropic hormone (ACTH), 87
Adsorption chromatography, 47
Aducanumab, 190
Advanced glycation end product (AGEs) levels, 66
Afnity chromatography (AC), 47
AG, see Angelica gigas
AGEs levels, see Advanced glycation end product
AKBA, see 3-O-Acetyl-11-keto-β-boswellic acid
ALA, see α-linolenic acid
Albumin, 136
Alginate, 136
Alkaloids, 21, 27, 55, 68–70
Allicin, 31, 227
Allyl-sulde sulphides, 32
Alpha 7 nicotinic acetylcholine receptors
Alpha-amino-3-hydroxy-5-methylisoxazole
α-linolenic acid (ALA), 28
ALS, see Amyotrophic lateral sclerosis
Alzheimer’s disease (AD), 1, 3, 4–5, 39, 61, 116,
AM P, see Adenosine monophosphate
AMPA, see Alpha-amino-3-hydroxy-5-
175–176
disorder
models
levels
(α7nAChRs) positive modulator, 61
propionate (AMPA), 87
126, 129, 207–209, 231
eugenol in, 190–193
neurohormetic phytochemicals reducing
symptoms of,
neuroprotective mechanisms of eugenol in, 192
methylisoxazole propionate
232
AMP-activated protein kinase (AMPK)
pathway, 59
Amphetamines, 99
Amyloid precursor protein (APP), 31, 59, 192
Amyloid-β peptide (Aβ), 4, 231
Amyotrophic lateral sclerosis (ALS), 1, 5, 126, 129
Angelica Archangelica L., 10
Angelica gigas (AG), 209
Annurca apple polyphenols, 210
Anthocyanins, 27, 151–152
Antibacterial and antiviral effect, 225–226
Anti-neuroinammatory phytoconstituents,
97–98
Antipsychotic medicines, 99
Anx iety, 22–23, 83
phytoconstituents used for, 87–88
related to separation, 23
Anxiolytic drugs, 6
Apigenin, 119
APP, see Amyloid precursor protein
Artemisia annua L., 210
Asafetida, see Ferula Assafoetida
ASD, see Autism spectrum disorder
Ashwagandha, see Withania Somnifera
Atmo Gas Capsule, 153
Atopic dermatitis (AD) mouse models, 212
Atropine, 57
Attention decit/hyperactivity disorder
(ADHD), 23
Attention/vigilance (AV), 101
Autism, 115
Autism spectrum disorder (ASD), 115, 232
neurohormetic phytochemicals reducing
symptoms of, 233
AV, see Attention/vigilance
Ayurveda, 99
Ayurveda, Yoga and Naturopathy, Unani,
Siddha and Homeopathy (AYUSH)
system, 125
B
Bacopa monniera (Brahmi), 8
Bacopa monnieri L., 101
BBB, see Blood-brain barrier
BChE, see Butyrylcholinesterase
BD, see Bipolar disorder
BDN F, see Brain-derived neurotrophic factor
Benincasa hispida, 101
241
242 Index
https://t.me/medicina_free
Benzodiazepines, 6
Berberine, 28–29, 58–59, 118, 155
β-carotenes, 212
Bevacizumab, 166
Bioactive phytochemicals, 21
Bioactive phytopharmaceutical, emerging
nanotechnology delivery approach for,
179–180
Biochemical activities, phytochemicals in the
regulation of
adaptive responses, stimulation of, 223–224
antibacterial and antiviral effect, 225–226
antioxidant and anti-inammatory effects, 224
DNA methylation, 224
enzyme activities, modulation of, 223
immune system, stimulation of, 225
tumour suppressor genes, induction of, 225
Biogenic gold nanoparticles, 131
Biopolymer-based nanoparticles, 133
Biotechnology application for better use of
neurophytomedicine, 154–155, 156
Biphasic dose responses, phytochemicals and, 234
Bipolar disorder (BD), 83
Blood-brain barrier (BBB), 9, 14, 26, 58, 60,
126, 129–130, 136–137, 138, 173,
178, 179, 187
BMS, see Brain monoaminergic systems
Boldine, 60
Bombyx mori, 209
Boswel l ic a cids, 175–176
in inducing apoptosis in tumour cells, 177
structures of, 176
BPRS, see Brief psychiatric rating scale
Brahmi, see Bacopa Monniera
Brain-derived neurotrophic factor (BDNF), 30,
32, 62, 86, 119, 189
Brain monoaminergic systems (BMS), 194
Brief psychiatric rating scale (BPRS), 100
Brief visuospatial memory test (BVMT), 101
Burseraceae, 11
Butyrylcholinesterase (BChE), 191
BVMT, see Brief visuospatial memory test
C
CA, see Cantella asiatica
CA1, see Cornu ammonis 1
Caffeine, 60
Cajaninstilbene acid, 98
Camellia sinensis L., 86
cAMP response element-binding protein (CREB),
32, 64, 98, 222, 223
Cannabidiol (CBD), 99–100
Cannabinoid, 100
Cannabis, 98
Cannabis sativa, 100
Cantella asiatica (CA), 226
Carbon nanotubes (CNTs), 138
Carotenoids (CT), 211–212
Cassia zelynicum, 194
Catechins, 227
Catechol-O-methyltransferase (COMT), 118
CBD, see Cannabidiol
CBT, see Cognitive behavioural therapy
CC, see Column chromatography
CCI-induced neuropathy, see Chronic
constriction injury-induced
neuropathy
CCK, see Cholecystokinin
CeA, see Central amygdala
Centella asiatica (mandookaparni), 8–9, 97
Central amygdala (CeA), 194–195
Central nervous system (CNS), 3, 21
CGI-S, see Clinical global impression
scale-severity
Chandan, see Santalum album
Chemotherapy, 166–168
bioactive phytopharmaceutical as adjuncts
to, 169
boswellic acids, 175–176, 176, 177
cu rcum in, 173 –175, 174
epigallocatechin gallate (ECGG),
176 –179, 177
querc etin, 172 –173, 172
resverat rol, 170 –172, 170
shortcomings of, 168–169
Chitosan, 136
1-(3-Chlorophenyl)piperazine hydrochloride
(mCPP), 102
Cholecystokinin (CCK), 87
Cholinesterase inhibitors, 27
Chromatographic techniques, 46
adsorption chromatography, 47
afnity chromatography (AC), 47
ion exchange chromatography, 47–48
partition chromatography, 47
size exclusion chromatography (SEC), 48
Chromatography, types of
column chromatography (CC), 49
gas chromatography (GC), 49–50
high-performance liquid chromatography
(HPLC), 50
paper chromatography (PC), 48–49
thin-layer chromatography (TLC), 49
Chronic constriction injury (CCI)-induced
neuropathy, 63
CIG, see Cornel iridoid glycoside
Cilengitide, 166
CJD, see Creutzfeldt-Jakob disease
Clinical global impression scale-severity
(CGI-S), 100
CNS, see Central nervous system
CN Ts, see Carbon nanotubes
Coffea arabica, 60
243Index
https://t.me/medicina_free
Cognition, 209
Cognitive behavioural therapy (CBT), 99
Cold extraction, 41–42
Colocasia esculenta, 101
Column chromatography (CC), 49
Commiphora whighitti, 11
COMT, see Catechol-O-methyltransferase
Continuous extraction, see Soxhlet extraction
Convolulus prostratus, 101
Convolutional neural network (CNN)-based
automated COVID screening
model, 214
Convolvulus pluricaulis, 101, 138
Coptidis rhizoma, 58, 155
Coriander, see Coriandrum sativum
Coriandrum sativum (coriander), 10
Cornel iridoid glycoside (CIG), 208
Cornu ammonis 1 (CA1), 191
Corticotropin-releasing factor (CRF) system, 87
Corticotropin-releasing hormone (CRH), 87, 97
COVID-19 pandemic, 145, 158
CREB, see cAMP response element-binding
protein
Creutzfeldt-Jakob disease (CJD), 1
CRF system, see Corticotropin-releasing factor
system
CRH, see Corticotropin-releasing hormone
Crocin, 102
Crocus sativus, 7–8, 98, 102
Cruciferous plants, 29
CT, see Carotenoids
CTL, see Cytotoxic T lymphocytes
Curcuma longa, 9, 96, 173
Curcumin, 25, 30–31, 102, 118–119, 173–175, 227
structure of, 174
Cuscuta chinensis, 152
Cyanidin-3-rutinoside, 27
Cyanoglucoside, 101
Cytochrome c (Cyt c), 59
Cytotoxic T lymphocytes (CTL), 228
D
Daffodil, 27
DA LYs , see Disability-adjusted life-years
DA production, see Dopamine production
Decoction, 41
Deep eutectic solvents, 43
Deep learning, 214
in natural product drug discovery and
development, 214–215
Degumming, 133
Dementia, 24, 39, 126
Demyelination, 6
Dentate gyrus (DG), 191
Deoxyribonucleic acid (DNA), 114
Depression, 23
eugenol in, 189–190
phytoconstituents used for, 88
anti-neuroinammatory
phytoconstituents, 97–98
hypothalamuspituitary-adrenal axis (HPA
ax is), 97–98
kynurenine pathway, inhibition of, 98
monoamine oxidase a inhibitors
DG, see Dentate gyrus
DHM, see Dihydromyricetin
Diallyl trisulde, 25
Digestion, 41
Dihydromyricetin (DHM), 209
Disability-adjusted life-years (DALYs), 2
Disease control, phytomedicine in, 156–158
DNA, see Deoxyribonucleic acid
DNA methylation, 224
DNA methylation mechanism (DNMTs), 121
DNMTs, see DNA methylation mechanism
Dopamine (DA) production, 99
Drosophila melanogaster, 59
(MAOI-A), 96
E
ECGG, see Epigallocatechin gallate
Enzyme activities, modulation of, 223
Epigallocatechin gallate (ECGG), 25, 26, 118,
Epigenetic modications by phytoconstituents in
Epilepsy, 24, 61
Eugenol, 187
132, 176 –179, 228–229
structures of, 177
neurological ailments, 114
epigenetic mechanism of neurological
disorders, 116 –117
epigenetic modications of the
phytochemical, 120–121
neurological disorder mechanism, 114
Alzheimer’s disease, 116
autism, 115
multiple sclerosis, 116
Parkinson’s disease, 116
sickle cell disease (SCD), 115–116
phytochemicals for neurological
disorder, 117
apigenin, 119
berberine, 118
curcumin, 118–119
epigallocatechin-3-gallate (EGCG), 118
limonoids, 119 –120
resveratrol, 119
and its properties, 188–189
neuroprotective effects and mechanisms of
Alzheimer’s disease,
depression, 189–190
Parkinson’s disease, 193–194
190 –193
244 Index
https://t.me/medicina_free
stress and stress-related disorders,
194–195
stroke, 195–196
traumatic brain injury (TBI), 196
Excitotoxicity, 24
Extraction, 39, 40
accelerated solvent extraction, 43
cold extraction, 41– 42
decoction, 41
deep eutectic solvents, 43
digestion, 41
infusion, 4 0 –41
maceration, 40
microwave-assisted extraction, 42
percolation, 41
pressurized liquid extraction (PLE), 43– 44
pulsed electric eld (PEF) extraction, 44
soxhlet extraction, 42
supercritical uid extraction, 43
ultrasound-assisted extraction, 42
F
Fabaceae, 11
False palisades, 163
Fatty acids, 28
Ferula Assafoetida (asafoetida), 9
FIS, see Fisetin
Fisetin (FIS), 212
Flavonoids, 21, 26–27, 151, 212–213
Forkhead box O (FOXO) family, 223
Fourier transform infrared spectroscopy
(FTIR), 52
FOXO family, see Forkhead box O family
Fractional crystallization, 46
Fractional distillation, 45–46
Fractional liberation, 46
Fractionation and purication techniques, 44
chromatographic techniques, 46
adsorption chromatography, 47
afnity chromatography (AC), 47
ion exchange chromatography, 47–48
partition chromatography, 47
size exclusion chromatography (SEC), 48
chromatography, types of
column chromatography (CC), 49
gas chromatography (GC), 49–50
high-performance liquid chromatography
(HPLC), 50
paper chromatography (PC), 48– 49
thin-layer chromatography (TLC), 49
fractional crystallization, 46
fractional distillation, 45–46
fractional liberation, 46
separation funnel technique, 45
sublimation, 46
French Paradox, 170
Fruits, phytochemicals in, 1
FTIR, see Fourier transform infrared
FUC, see Fucoxanthin
Fucoxanthin (FUC), 211
spectroscopy
G
GABA, see Gamma amino butyric acid
see Generalized anxiety disorder
GAD,
Galantamine, 60–61
Gamma amino butyric acid (GABA), 57, 87, 119
Gas chromatography (GC), 39, 49–50
Gastrodia elata, 96
GBM, see Glioblastoma multiforme
GC, see Gas chromatography
GCI, see Global cerebral ischemia
GCs, see Glucocorticoid receptors
Generalized anxiety disorder (GAD), 23
Genetic disorders, 114
GFR, see Growth factor receptors
Ginkgo biloba, 207
Ginsenoside Ro (GRo), 211
Glioblastoma multiforme (GBM), 161
bioactive phytopharmaceutical, emerging
nanotechnology delivery approach for,
179 –180
characteristics of, 162
chemotherapy, bioactive phytopharmaceutical
as adjuncts to, 169
boswellic acids, 175–176, 176, 177
curcumin, 173 –175, 174
epigallocatechin gallate (ECGG),
176 –179, 177, 178
quercetin, 172–173, 173
resveratrol, 170–172
future prospectives, 180 –181
oncogenic signalling pathways involved in, 164
pathogenesis of, 162
oncogenic pathways, 163 –164
unique histopathology, 163
phytopharmaceuticals, regulatory aspect
of, 180
temozolomide (TMZ) and, 162, 166–168,
169, 170
therapeutic approaches to, 165
chemotherapy, 166 –168
chemotherapy, shortcomings of, 168–169
radiation therapy, 165–166
su rger y, 165
Global cerebral ischemia (GCI), 61
GLT-1, see Glutamate transporters 1
Glucocorticoid receptors (GCs), 97
Glutamate, 87
Glutamate-induced excitotoxicity, 61
Glutamate transporters 1 (GLT-1), 61
Glycosides, 152
245Index
https://t.me/medicina_free
Glycyrrhiza glabra, 11
GPCR, see G-protein coupled receptors
G-protein coupled receptors (GPCR), 32
Green synthesized nanoparticles, 137–138
GRo, see Ginsenoside Ro
Growth factor receptors (GFR), 32
Guggulu, see Commiphora whighitti
Gynostemma pentaphyllum, 209
H
HAC P, see Helicteres angustifolia L
Haldi, see Curcuma Longa
HAND, see HIV-associated neurocognitive
Harmine, 61–62
HD, see Huntington’s disease
HDAC9 gene, 117
Health care system, phytomedicine and, 149
Heat shock proteins (HSPs), 232
HedC, see Hederoside C
Hederoside C (HedC), 210–211
Helicteres angustifolia L (HACP), 225
Herbal medications, 1
Herbal medicine, 227
Herbs, medicinal properties of, 13
High-performance liquid chromatography
HIV-associated neurocognitive disorders
hMD2, see Human myeloid differentiation
Hormesis-induced memory performance,
Hormetic studies
HPA axis, see Hypothalamus-pituitary-adrenal
HPLC, see High-performance liquid
Hs p27, 172
HSPs, see Heat shock proteins
5-HT, see 5-Hydroxy tryptamine
Human medical care, application of
Human myeloid differentiation factor-2
Huntington’s disease (HD), 1, 3, 5–6, 61, 126,
Huperzia serrate,
Huperzine, 62–63
disorders
(HPLC), 39, 50
(HAND), 1
factor-2
228–229
Alzheimer’s disease, 231, 232
autism spectrum disorder (ASD), 232, 233
Huntington’s disease (HD), 230–231, 231
Parkinson’s disease (PD), 229, 229
schizophrenia, 230, 230
axis
chromatography
phytomedicine in, 146 –148
(hMD2), 191
129, 230–231
neurohormetic phytochemicals reducing
symptoms of, 231
62
Huperzine A, 28
Hydrastis canadensis, 155
Hydrogen peroxide, 27
6-Hydroxydopa mine (OHDA), 25, 28, 60, 193
5-Hydroxy tryptamine (5-HT), 23, 87
Hyperforin, 102
Hypericin, 30, 102, 227
Hypothalamus-pituitary-adrenal axis (HPA axis),
83, 97–98, 194
I
Identication of phytochemicals, 50, 51
infrared (IR) spectroscopy, 52
mass spectroscopy (MS), 53
nuclear magnetic resonance spectroscopy
(NMR), 52–53
UV–visible spectroscopy, 51–52
IL -1, see Interleukin-1
IL-1 beta levels, 97
Immune function
neurohormetic phytochemicals regulating,
227–228
stimulation of, 225
Indole alkaloids, 27
Infantile autism, 115
Infrared (IR) spectroscopy, 52
Infusion, 40– 41
Insomnia, 83
phytoconstituents for, 103
Insulin receptors (IR), 32
Interleukin (IL)-1, 225
Ion exchange chromatography, 47–48
IR, see Insulin receptors
I/R injury, see Ischemia/reperfusion injury
IR spectroscopy, see Infrared spectroscopy
Ischemia/reperfusion (I/R) injury, 60
J
Jun N-terminal kinase (JNK) protein
phosphorylation, 86
K
Kainic acid, 87
Korean red ginseng (KRG), 86
Koumine, 63
KRG, see Korean red ginseng
Kynurenine pathway, inhibition of, 98
L
LA, see Linoleic acid
Lactate dehydrogenase (LDH), 62
Lagenaria leucantha Rusby, 102
Lamiaceae, 11
Соседние файлы в папке Библиотека им академика М.И. Перельмана